Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：10

作者：

Huang, Linjuan ^{[1
,2
,3
,4
]}

Zhang, Jing ^{[1
,2
,3
,4
]}

Deng, Youling ^{[1
,2
,3
,4
]}

Wang, Hao ^{[4
,5
,6
]}

Zhao, Piao ^{[1
,2
,3
,4
]}

Zhao, Guozhi ^{[1
,2
,3
,4
]}

Zeng, Wei ^{[4
,7
]}

Wang, Yonghui ^{[4
,8
]}

Chen, Connie ^{[4
]}

Wagstaff, William ^{[4
]}

Haydon, Rex C. ^{[4
]}

Reid, Russell R. ^{[4
,9
]}

He, Tong-Chuan ^{[4
,10
]}

Shen, Le ^{[4
,10
]}

Luu, Hue H. ^{[4
]}

Zhao, Ling ^{[1
,2
,3
,4
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China

[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China

[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China

[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA

[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China

[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China

[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China

[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China

[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA

[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA

来源：

GENES & DISEASES | 2023年 / 10卷 / 04期

基金：

美国国家卫生研究院;

关键词：

Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;

D O I：

10.1016/j.gendis.2022.12.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic

引用

页码：1687 / 1701

页数：15

共 91 条

[1] Cisplatin resistance and opportunities for precision medicine [J].

Amable, Lauren .

PHARMACOLOGICAL RESEARCH, 2016, 106 :27-36

[2] Bone morphogenetic protein 4 (BMP4) promotes hepatic glycogen accumulation and reduces glucose level in hepatocytes through mTORC2 signaling pathway [J].

An, Liqin ;

Shi, Qiong ;

Zhu, Ying ;

Wang, Hao ;

Peng, Qi ;

Wu, Jinghong ;

Cheng, Yu ;

Zhang, Wei ;

Yi, Yanyu ;

Bao, Zihao ;

Zhang, Hui ;

Luo, Yetao ;

Fan, Jiaming .

GENES & DISEASES, 2021, 8 (04) :531-544

[3] Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer [J].

Arend, Rebecca C. ;

Londono-Joshi, Angelina I. ;

Samant, Rajeev S. ;

Li, Yonghe ;

Conner, Michael ;

Hidalgo, Bertha ;

Alvarez, Ronald D. ;

Landen, Charles N. ;

Straughn, J. Michael ;

Buchsbaum, Donald J. .

GYNECOLOGIC ONCOLOGY, 2014, 134 (01) :112-120

[4] Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities [J].

Barbosa, Eduardo Jose ;

Lobenberg, Raimar ;

Barros de Araujo, Gabriel Lima ;

Bou-Chacra, Nadia Araci .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2019, 141 :58-69

[5] Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial [J].

Burock, Susen ;

Daum, Severin ;

Keilholz, Ulrich ;

Neumann, Konrad ;

Walther, Wolfgang ;

Stein, Ulrike .

BMC CANCER, 2018, 18

[6]

Cao DG, 2020, AM J CANCER RES, V10, P3248

[7] Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling [J].

Chen, Bin ;

Wei, Wei ;

Ma, Li ;

Yang, Bin ;

Gill, Ryan M. ;

Chua, Mei-Sze ;

Butte, Atul J. ;

So, Samuel .

GASTROENTEROLOGY, 2017, 152 (08) :2022-2036

[8] All-trans retinoic acid reverses malignant biological behavior of hepatocarcinoma cells by regulating miR-200 family members [J].

Cui, Jiejie ;

Gong, Mengjia ;

Fang, Shuyu ;

Hu, Chaoqun ;

Wang, Yi ;

Zhang, Jingfang ;

Tang, Ni ;

He, Yun .

GENES & DISEASES, 2021, 8 (04) :509-520

[9] A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities [J].

Deng, Youlin ;

Wang, Zhongliang ;

Zhang, Fugui ;

Qiao, Min ;

Yan, Zhengjian ;

Wei, Qiang ;

Wang, Jing ;

Liu, Hao ;

Fan, Jiaming ;

Zou, Yulong ;

Liao, Junyi ;

Hu, Xue ;

Chen, Liqun ;

Yu, Xinyi ;

Haydon, Rex C. ;

Luu, Hue H. ;

Qi, Hongbo ;

He, Tong-Chuan ;

Zhang, Junhui .

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 39 (03) :871-888

[10] Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells [J].

Deng, Youlin ;

Zhang, Junhui ;

Wang, Zhongliang ;

Yan, Zhengjian ;

Qiao, Min ;

Ye, Jixing ;

Wei, Qiang ;

Wang, Jing ;

Wang, Xin ;

Zhao, Lianggong ;

Lu, Shun ;

Tang, Shengli ;

Mohammed, Maryam K. ;

Liu, Hao ;

Fan, Jiaming ;

Zhang, Fugui ;

Zou, Yulong ;

Liao, Junyi ;

Qi, Hongbo ;

Haydon, Rex C. ;

Luu, Hue H. ;

He, Tong-Chuan ;

Tang, Liangdan .

SCIENTIFIC REPORTS, 2015, 5

← 1 2 3 4 5 6 7 8 9 10 →